Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Saturday, May 25, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

Rigel Pharmaceuticals inflated its share price by issuing false and misleading information about clinical trials and prospects for its R788 drug, shareholders say in San Francisco Federal Court. Shareholders say share price tripled after the allegedly misleading press release.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...